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Abstract
This mini review aims to describe the main physicochemical properties and characteristics of cyclodextrin derivatives (CDs) having
been used in various skin-related formulations over the last nearly 50 years. Due to many misunderstandings and inconsistent
data on the Internet, the basic properties of CDs, water content, solubility properties, and maximum complexing capabilities are
summarized. CDs are grouped by their solubility properties and briefly described by chemical synthesis to reveal the potential
contaminants. Soluble and insoluble CD-based polymers are also discussed.
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1. Context
Cyclodextrins and their derivatives are common drug
carriers, and their topical application has gained inter-
est since the beginning of their widespread dissemina-
tion in the last decades of the 20th century. Although the
application idea of these drug carriers is not new, their
physicochemical and major physiological properties are
less known for the applicants, scientists, and practition-
ers outside the specialized laboratories. In this paper,
the main chemical characteristics, production methods,
and properties of currently used or potentially suitable cy-
clodextrin derivatives are discussed.
2. Introduction
Cyclodextrins (CDs) are natural cyclic oligosaccha-
rides, whose constitution unit is the αD-glucopyranoside.
This family of cyclic carbohydrates is often referred to
as cyclomaltooligosaccharides, showing the maltose-type
glycosidic connection between the glucose units. These
constituents are linked together by α (1 → 4) glucoside
bonds, and although the most commons are the 6, 7, and
8 units containing versions (namely, α-, β-, and γCDs) (1),
the largest cyclic structures have more than 150 glucopyra-
noside units (2).
Recently 3- and 4-membered CDs have also been syn-
thesized (3), but the 5-membered version is the smallest
known structure with a cavity (4). These CDs have poor
practical importance though they well demonstrate the
developments in the oligosaccharide syntheses. While the
6 - 10 units containing CDs have truncated cone structures,
the hole formed by the carbohydrate units is less distorted
in the 6 - 8 membered natural CDs (2). The two hydrophilic
hydroxyl rims embrace a relatively less hydrophilic struc-
ture, and the cavity is suitable to form adducts with proper
chemical structures, like long alkyl chains, aromatic rings,
etc.
Owing to the connecting glycosidic oxygens, the for-
mation of H-bonded networks or other non-covalent inter-
actions is possible with appropriate molecules. The two hy-
droxyl rims are not equally hydrophilic. The secondary hy-
droxyls form a rigid and strong hydrophilic barrier toward
the cavity, while the primary hydroxyls are more flexible,
making the rim slightly less hydrophilic. In solution, these
primary hydroxyl groups (as CH2OH groups) can rotate al-
most freely, creating a continuously opening and closing
door for the cavity. Although their mobility is significantly
limited in the solid state, the thermal movement of these
groups gives some flexibility to the macrocycle.
The non-covalent associations are generally referred
to as “host-guest” or “inclusion” complexes, although in
many cases, especially in solutions, the guest molecule has
a short average residence time within the cavity. In cases
where the guest is large enough, like complex molecules,
other macrocycles, oligopeptides, or proteins, the asso-
ciation is restricted to an appropriate part of the large
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molecule (5).
It is also common that the molecular composition is
different from the 1:1 host:guest ratio or the complexes cre-
ate large associations in solutions. The complex stability
constant, which characterizes the dynamic equilibrium,
is generally within the range of 100 - 3000 M-1, typically
around 500 M-1 in the case of 1:1 complexes (6). Though
this stability constant is apparent because some complex
compositions, like 1:1 and 2:2, cannot be distinguished or
the low concentrations of other compositions allow their
elimination to simplify the calculations.
In many cases, CDs form insoluble complexes, as well.
These insoluble complexes have made the ton-scale CD pro-
duction feasible. The CD production is a green process
because not only the raw materials are vegetable polysac-
charides, but the waste is also suitable for alcohol produc-
tion. Isolation techniques of more than 8-membered or the
branched CDs, which have one or more glucose-based pen-
dant groups, generally use chromatography, which mo-
mentary restricts them into research laboratories.
Cyclofructins are also cyclic oligosaccharides with a
cavity, based on fructose, which is also a glucose isomer.
Due to their less rigid and symmetric structure, that cavity
has somehow different physicochemical properties. How-
ever, nowadays, their price has limited their application (7,
8).
Natural (“naked”) cyclodextrins have been known for a
long time, and numerous CDs have been accepted as drug
carriers and included in the GRAS food list for many years
(www.fda.gov/food/food-ingredients-packaging/generally-
recognized-safe-gras). The topical toxicity of more com-
mon CDs is exhaustively discussed (9). Cyclodextrins have
a relatively large margin of safety in all dermal applica-
tions and can not only be used exclusively for optimized
transdermal drug vehicles for topical or systemic delivery,
but also used in skin protection formulations (10) and
cosmetics (11, 12). CDs generally improve the solubility
and/or stability of drugs in topical formulations, promote
the transdermal absorption of drugs, and can control the
release of active ingredients. However, the penetration of
the CDs themselves through the skin is very limited (7, 9,
13, 14), which can reduce the drug’s side effects (15).
Natural CDs and numerous CD derivatives are chem-
ically stable in a wide range of pH. The lack of reducing
end makes the macrocycle extremely stable under basic
conditions. It is necessary to note that commercially avail-
able native CDs always contain some residual linear dex-
trins. The reducing-end of these impurities is unstable in
the presence of a base and/or higher temperatures, which
results in yellow-to-brown coloration. The glycosidic bond
can be cleaved easily in strongly acidic solutions (> 0.01N
concentration of HCl, H2SO4, HClO4, etc.) (16, 17), in car-
boxylic acid solutions at higher temperatures (18), or in an-
hydrous Lewis acids at moderately high temperatures (19).
Nowadays, many utilizations of CDs can be found on
the Internet, starting from their use as catalysts in syn-
thetic chemistry to analytical applications, drug carriers,
food ingredients. The general discussion of CD properties,
synthesis of their derivatives and their application is well
summarized in recent books of Fourmentin et al. (20, 21)
The idea of application of CDs or their derivatives either
in skin formulations (and cosmetics) or as drug carriers
for other topical deliveries emerged relatively soon in the
blowing era of CD derivatizations (22-26). Application of
CDs as solubility enhancers for otherwise poorly soluble
small molecules has also become common in the biochem-
ical production processes for a long time (27-29). The first
review of CDs in skin applications appeared in the early
stages of CD industrialization, but only a few new CDs have
been tried since then, and even fewer have become com-
mercialized formulations (23, 24, 30-34). Despite their high
formulation potential, relatively easy toxicological stud-
ies, and early start of publication activity, the skin-related
technical papers represent only a minority (≈ 7%) in all
publications, even within the pharmaceutical and cosmet-
ics subgroup. Due to keywords multiplication in technical
papers, the absolute values in Figure 1 are less important.
3. Discussion
There are several ways to classify CDs, and due to the
limited number of pharmaceutically acceptable CD deriva-
tives, this discussion based on solubility seems reasonable.
Since water-soluble CDs are the most used compounds
in parenteral and oral formulations, insoluble derivatives
can be more suitable for certain extracorporeal formula-
tions, either in pharmaceutical or cosmetic products. Due
to the widespread presence of the cosmetics industry, skin
products are in a favorable position, and the common in-
terest in the pharmaceutical industry can synergize test-
ing periods.
Table 1 summarizes the most frequently studied CDs,
in which solvents are more important from the synthetic
view, and the less common organic solvents are ignored.
Although even natural CDs are soluble in so-called “dipo-
lar aprotic” organic solvents, their use is less common in
the preparation of CD complexes or formulations. Other
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Figure 1. Publication distribution of skin-related formulations by keywords
organic solvents are generally limited to lower alkyl alco-
hols and acetone.
Usually, the high molecular weight (MW) of naked CDs,
as compared to the guest molecules, is a serious drawback.
Assuming the most common 1:1 host-guest ratio (which
is rarely really achieved in the prepared complexes), the
weight ratio of a potential guest molecule is less than
30% at a theoretical MW of 400 Da. Although that ratio
is rather more problematic in the parenteral applications
than in skin formulations, the MW and dosage of the guest
molecule is crucial and restricts the utilization of CD com-
plexes. Obviously, the derivatization of CDs further re-
duces this ratio (Table 1), and this is even more important
in the cases of polymerized CDs, which can explain the lim-
ited number of tested derivatives.
3.1. Soluble CDs and CD Derivatives
3.1.1. Water-Soluble CDs and CD Derivatives
While natural CDs are crystalline compounds, the most
useful randomly derivatized versions are amorphous ma-
terials. These CDs are compositions of differently substi-
tuted CDs and contain numerous regional isomers, as well.
Aqueous solubilities are varied and while the natural βCD
is relatively poorly soluble (~ 2%) in water, the solubility
of randomly decorated variants is almost unlimited. In
the shelf-dry form, as available from the suppliers, naked
CDs contain a more or less constant amount of water (10%
- 14%). Although about half of the crystal water can be
readily removed at a moderately high temperature, the
complete drying requires more drastic conditions. Most
of the water-soluble derivatized CDs contain considerably
less residual water, usually in the 3% - 6 % range, which can
likewise be removed under moderate conditions. While
the complete drying of both natural and derivatized CDs
is relatively easy, water resorption is just as easy.
Although the physicochemical properties of the most
common α-, β-, and γCDs are easy to find in various
printed and internet sources, many of them are often mis-
understood, forgotten or, what is even worse, neglected.
The crystal water of natural CDs considerably affects not
only the weighing of CDs and aqueous solubilities, but
the completely dried CDs are also hygroscopic and very
electrostatic materials (36). Additionally, the water-guest
molecule exchange is not a one-direction process. Usually,
not only the release of the guest molecule needs the active
participation of water, but in case of its absence, the for-
mation of the inclusion complex is strongly inhibited, too
(37).
A further misunderstanding is the polar-
ity/hydrophobicity of the cavity. Both properties are
relative and usually compared to water. “Hydrophobic
cavity is suitable to form inclusion complexes with hy-
drophobic guests” can be often found in the literature and
this statement forcibly suggests that only hydrophobic
molecules are suitable for the complexation. But this is
not the case! Although the first publication on this old
scientific problem set the cavity polarity to the n-octanol
range, the detailed spectrofluorometric investigation re-
vealed its mid polarity (38-41). The cavity polarity is around
the 1:1 (v/v) EtOH-water mixture, which makes this mixture
a magic solution which can decompose the majority of
complexes.
Hydrophobicity/lipophilicity is another question. This
property does not have an absolute scale. Although the
most commonly used parameter, logP value (logarithm
of the partition coefficient (P), between a mixture of wa-
ter and n-octanol at equilibrium, recently mostly logPo/w,
can be experimentally measured, the solubility of the
molecules in n-octanol is a serious shortcoming. The logP
can be computed, and although there are many sophisti-
cated software programs for these calculations, the values
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α-cyclodextrin αCDe 1.03 9 - 11 ~ 10 DMF, DMSO, Pyf
β-cyclodextrin βCD 0.88 13 - 14 ~ 2 DMF, DMSO, Py
γ-cyclodextrin γCD 0.77 9 - 11 ~ 15 DMF, DMSO, Py
Partially acetylated
βCD
Ac7βCD DS = 7 - 8 0.69 3 - 5 > 40 MeOH, AcOH
Heptakis(2,3,6-tri-O-
acetyl)-βCD




CRYSMEB DS ≈ 4 - 6 0.83 3 - 5 ~ 10 DMF, DMSO, Py








DIETBi DS = 14 0.65 < 1 DMF, DMSO, CHCl3
(2-hydroxy)
propylated βCD
HPβCD DS ≈ 3 - 3.5 0.76 3 - 6 > 40 MeOH, EtOH (limited)
(2-hydroxy)
propylated βCD
HPβCD DS ≈ 4 - 5 0.72 3 - 6 > 40 MeOH, EtOH
(2-hydroxy)
propylated βCD
HPβCD DS ≈ 6 - 7 0.66 3 - 6 > 40 MeOH, EtOH, acetone
(2-hydroxy)
propylated γCD
HPγCD DS ≈ 4 - 5 0.64 3 - 6 > 40 MeOH, EtOH (limited)
(2-hydroxy) ethylated
βCD
HEβCD DS ≈ 4 - 5 0.75 > 40 MeOH
Carboxymethylated
βCD sodium salt




CMEβCDj N/A N/A N/A N/A
Carboxyethylated βCD
sodium salt
CeβCDj DS ≈ 3.5 - 4.5 0.66 3 - 6 > 30
Sulfobutylated βCD
sodium salt
SBEβCDj , k DS ≈ 6 - 7 0.51 3 - 6 > 30





N/A 0.58 3 - 6 > 30 DMF, DMSO
Insoluble βCD
polymerl
βCDPI N/A 0.58 1 - 2 N/A
Nanospongem NS N/A ND ND > 30 DMF, DMSO
Abbreviations: CH2Cl2 : methylene chloride; CHCl3 : chloroform; DMSO: dimethyl sulfoxide; DMF: N,N-dimethyl formamide; EtOH: ethanol; MeOH: methanol; N/A: not
applicable; ND: no data; Py: pyridine; SBE: sulfobutyl ether.
aThe randomly (statistically) derivatized CDs are characterized by DS (degree of substitution = average number of substituents/ring, pharmacopeia recommended cal-
culation from 1H-NMR). Due to quality assurance reasons the producers often give a wide range for DS (sometimes as substituent/glucose unit!).
bThe middle values of DS are used, polymers are calculated with 60% CD content.
cFrom product catalogs of main CD suppliers; the exact value is the certificate of analysis.
dShelf-dry, as can be received from suppliers.
eSometimes CyD is also used.
f Poorly soluble complex formation with the solvent.
gRarely MβCD, PMβCD, or RMβCD is used, as of methyl-, partially methylated, or randomly methylated βCD.
hMany differently methylated derivatives use this name. The most common product is the DIMEB50, which contains < 40% heptakis(2,6-di-O-methyl)-βCD, despite its
unreasonably low heptakis content. The larger number after “DIMEB” refers to higher heptakis content, e.g. DIMEB95 contains > 95% heptakis(2,6-di-O-methyl)- βCD.
iAbnormal solubility-temperature profile. Solubility at 100°C < 2%.
jAs the sodium salt.
kSometimes SBβCD is also used, because “E” is useless and redundant for “ether” and missing in the nicknames of HE/ET/HP/ME/CM, etc. derivatives.
lEpichlorohydrin crosslinked CD polymer, CD content is around 55% - 60%.
mVarious derivatives; many different kinds of linkers are in this class, see the text and the Trotta’s review (35).
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of different programs do not always match. Experimental
data on various complexes provide good evidence for the
discrepancy between the declared hydrophobic cavity and
the complexation of water (37), inorganic (42, 43) and or-
ganic, particularly sulfonic acid, salts (39). As a conclusion:
the CD cavity is only considerably less hydrophilic than the
hydroxyl rims of CDs or the aqueous macro-environment.
The high hydrophilicity of water-soluble CDs, as a big
advantage, limits their absorption through the skin. It is
necessary to mention that despite the unchanged number
of hydroxyl groups, the (2-hydroxy)propyl derivatives are
less hydrophilic than the parent CDs. The methyl substi-
tution, despite the lipophilic methyl groups, increases the
aqueous solubility. The explanation is the modification of
the rigid hydrophilic secondary OH-rim: methylation re-
duces the ability to form hydrogen-bridged macromolec-
ular associates between CDs. Water-soluble CDs are also
suffering a noticeable disadvantage: the solubility in wa-
ter. Without protection, like in patches, CDs and their com-
plexes are readily removed from the skin, reducing the ef-
fective absorption of the active ingredient.
However, the wash-off phenomenon is a beneficial ef-
fect: the accumulation of CDs on the body surface is pre-
vented. In the mid-1990s, there was a brief, but rather
a self-evident, debate about the accumulation of carcino-
gens in the gastrointestinal tract by CDs of oral drug for-
mulations (44, 45). Considering the basic physicochemi-
cal processes, it was more about money than a real threat.
The complex formation is a concentration-driven dynamic
equilibrium. It is difficult to believe that the picomolar,
but rather less, presence of harmful chemicals can consid-
erably be complexed, and so they could be accumulated
by CDs. Although the accumulation of undesirable sub-
stances on the skin may be more pronounced, it is less
likely than in the mentioned case. Additionally, exactly wa-
ter solubility of CDs is what can eliminate this threat, and
they are washed off before the accumulation of any com-
ponents from the environment.
How are CDs prepared? Although the pure chemical
synthesis of CDs is solved, that way is nothing else than
an interesting challenge for organic synthetic chemists.
The preparation of CDs is still based on a more than 100
years methodology (1), only the living organism is sub-
stituted with isolated, sometimes genetically engineered
and fine-tuned, enzymes (46). The cyclization of the pre-
formed amylose fragments is done by various enzymes,
but dominantly a variant of cyclodextrin glucosyltrans-
ferase (CGTase). This type of enzymes are also known as
cyclodextrin glycosyltransferase or cyclodextrin glucan-
otransferase, but because CDs are constructed per defini-
tionem from α (1→ 4) linked glucosides, the first alterna-
tive is more correct.
The book of Jin (47) is a basic source on the enzymatic
production of CDs. The isolation of products depends on
the use or lack of organic complexants or solvents in the
conversion mixture. The traditional synthesis allows the
preparation of isotope labeling of CDs in the “core”. In iso-
lated environments, the enhancement of 14C isotope as CO2
is built into the constituting glucoside units. Of course,
the lack of control means that the incorporation of the iso-
tope is necessarily random (48). The complete elimination
of the complexant from the products from the conversion
mixture is crucial (49). The incomplete removal of toxic or-
ganics has led to the stigmatization of CDs as toxic materi-
als by the first misinformation on the toxicity of CDs (50).
Although it is true that not all CDs, like not all inorganic
or organic materials, can be administered parenterally, but
CDs themselves are not ab ovo toxic substances, as can be
seen in various medical, food, cosmetics, or other house-
hold utilizations.
Apart from naked CDs, among the studied CD deriva-
tives the ionic and soluble polymeric derivatives are sol-
uble almost exclusively in water. These are the car-
boxymethylated (CM), carboxyethylated (CE), sulfobuty-
lated (SB), and polymerized CDs. It is also true that
nanosponges may contain some acidic end groups and
those derivatives are considered neutral. Although most of
the water-soluble CDs are also soluble in some organic sol-
vents, in this section, the DMF, DMSO, or pyridine-like sol-
vents are excluded. The removal of those chemicals after
derivatization reactions, or exclusion from formulations,
is an obvious demand.
Ionic CD derivatives are almost insoluble in all organic
solvents either in ionized or protonated forms, although
counterions can affect their solubility. The ionic forms of
both carboxylic and sulfoalkylated CDs are chemically sta-
ble. They are very hydrophilic molecules, and the dom-
inant substitution location is on the secondary hydroxyl
side. The protonated form makes these derivatives chem-
ically labile. Organic acid (carboxylic acid) derivatives are
capable of reversibly forming molecular and molecular es-
ters, and sulfonic acids are strong acids and can destroy
the macrocycle. The general synthetic procedure of neu-
tral and ionic alkylated CDs is summarized in Figure 2A.
Soluble CD polymers (CDPS) have complicated 3D
structures. Not only because of the different reactivities
of the CD hydroxyls, but the bifunctionality of the linkers
inheritably results in sidechains that cannot be attached
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Figure 2. General synthetic method of the water-soluble A, monomeric; B, polymeric cyclodextrin derivatives; C, the major structural differences between CDPS and
nanosponges. N = 0 αCD; n = 1 βCD; n = 2 γCD.
to other CDs. Although “linear” CD polymers have also
been synthesized (51), the complex synthesis shifts their
use in potential formulations to the distant future, if pos-
sible at all. In general, polymerized CDs can be divided
into two major subgroups: CD polymers (CDP) meaning
that usually the chemically stable bond crosslinks CDs (52,
53), and the hydrolyzable nanosponges (NS) (35). The syn-
thetic routes of ether-linked CDPs are shown in Figure 2B,
while the syntheses of dominantly acyl group-linked NS
are in Figure 3. There is a third, momentarily very minor
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group but in chemical terms in the neighborhood of NS:
the co-polyesters of multicarboxylic acids, like citric, glu-
taric, adipic, etc. acids (35, 54, 55).
A cuckoo nest inside the NS is the hemiacetal-linked
version that is much more labile than esters and is de-
graded even by very weak acids, too. Despite their simi-
larity to the NS, their application is very limited (55). The
acidic crosslinkers form esters, but the acidic end groups
can also trigger their acid-catalyzed hydrolysis, which can
considerably modify the polymeric structure. Due to the
poorly characterized structures and the few applications,
particularly in the skin and cosmetics area, their synthetic
method is mentioned tangentially only in Figure 3. The
poor reproducibility of the synthesis and aging are the
most common problems of CDPs. The reactive end groups
of the bifunctional chemical reagents react not only with
CDs but also with water, even in the solid products. Be-
cause of the poor chemical characterization, the substitu-
tion patterns in these CDs are not clear.
Some noncovalent associations, like rotaxanes, are also
called CD-polymers (56). Even though the complexed com-
ponent is polymeric, these CD derivatives are not CD poly-
mers. In some cases, the polymeric backbone attached to
CDs are also classified as CD polymers, but they are rather
polymers with some CD content than CD polymers.
Through the combination of the polymerization re-
action with another alkylation, like methylation or car-
boxyalkylation, the microenvironment can be readily fine-
tuned, at least theoretically. Komiyama (57), the contem-
porary “father” of modern CD chemistry, presented the
outlines of molecular imprinting, which was recently re-
viewed by Lay et al. (58). The linkers are dominantly lo-
cated on the secondary hydroxyl rims, and often CD units
bear many (2,3-dihydroxy)propyl or, in general, (2,ω,ω-
trihydroxy)alkyl sidechains. The synthetic route of CDPs is
shown in Figure 2B.
NSs are prepared by the reaction of CDs with various ac-
tivated carbonyl compounds, like triphosgene, dicarbon-
ates, carbonyldiimidazole, dianhydrides, diisocyanates, or
2,2-bisacrylamidoalkyl acids. These reactions result in car-
boxylic derivatives, and the syntheses show similarities to
the amphiphilic CD esters, as seen in Figure 3. In NS typi-
cally three kinds of chemical bonds connect CDs and link-
ers: ester (35), carbamate (59), and eventually amide (60).
The latter is not classical NS, because the ether-bound link-
ers are connected to each other with amide bonds.
Although numerous publications are discussing the
application of NS, their spread is still poor despite their
sometimes excellent physicochemical properties. The lim-
ited number of applications are not exclusively bound to
their poor shelf-life or weak synthetic reproducibility, but
rather the preparation of numerous different derivatives
without a lead. The review of Tejashri et al. (54) well sum-
marizes the variability of NS among the potential drug
formulations. The numerous CDs in NS increase the MW,
which further worsens the host:guest mass ratio. Although
it is difficult to find general considerations for the substi-
tution patterns in various NSs, the preparation methods
suggest similarities to the alkyl-type soluble polymers. The
general structural differences between CD polymers and
NS, without the (hemi)acetal version, are shown in Figure
2C.
Although the poor guest weight ratios in CDP formula-
tions are less suitable for parenteral, oral, or mucosal de-
livery, it is less important in dermal applications (61) or for
the less price-sensitive cosmetics.
3.1.2. CD Derivatives Soluble in Water and Organic Solvents
These amphiphilic CD derivatives are suitable for both
solubilization of drugs and their controlled release. Their
aqueous solubility allows their easy removal from the skin,
which is especially useful in cosmetics and skin care prod-
ucts. The good solubilization properties also decrease the
possible overdosing. The associations between the CD
molecules are greatly reduced by the breaking of the sym-
metry and hydrogen bonds in the rigid hydrophilic rim,
which thereby provides an increased aqueous solubility
and a larger flexible cavity. Some derivatives are soluble not
only in alcohols but also in acetone and toluene, which is
useful in their purification processes.
It is necessary to mention that CDs in this section are
not “amphiphilic” CD derivatives. “Amphiphilic” CDs form
a subgroup of differently substituted CDs, containing both
hydrophilic (hydroxyalkyl/carboxyalkyl) and hydrophobic
(fatty acid esters, -carbamates) moieties. Although those
CD derivatives are tested in various targeted drug delivery
formulations, their appearance in dermal formulations is
negligible.
Only a few derivatives are in this class: the (2-
hydroxy)propylated, the partially acetylated, and the > 13
methyl groups substituted CDs (actually, only the DIMEB).
The increasing DS moves the HP-CD solubility from MeOH
toward the longer alkyl alcohols. While the oldest DS≈ 3
- 3.5 HPβCD is freely soluble in MeOH and partially only in
EtOH, the DS≈ 4.5 is well soluble in MeOH and EtOH, and
the DS≈ 6.5 is freely soluble in EtOH. A similarly increased
solubility can be found in acetone, which is widely used to
remove the formed 1,2-propylene glycols in their produc-
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Figure 3. General synthetic method of acylated CD derivatives and nanosponges. N = 0 αCD; n = 1 βCD; n = 2 γCD.
tion.
Since the low DS HPPβCDs can be “recrystallized” from
MeOH by the addition of acetone, the DS ≈ 6.5 HPβCD is
freely soluble in acetone. Of course, in aqueous solutions
of these solvents, those derivatives have unlimited solubil-
ity. Partially acetylated CDs are freely soluble in water and
MeOH, and even also in toluene, but the insoluble toluene
complex starts to precipitate within a short period. This
complexation can be utilized in purification processes.
The synthesis of the partially acetylated CD derivatives is
shown in Figure 3. Although DIMEB is well soluble in MeOH
(and acetone) until the heptakis(2,6-di-O-methyl)βCD con-
tent is low (< 55% - 60%), the increasing heptakis con-
tent considerably decreases its solubility. The solubility of
DIMEB in acetone is tricky: after dissolution, as the poorly
soluble acetone complexes formed, the heptakis- and± 2
methylated CDs begin to precipitate soon. Recrystalliza-
tion of the DIMEB/acetone complex from MeOH increases
the heptakis content up to 85% - 90% and removes the ace-
tone. However, RAMEB, which contains only < 13 methyl
groups on the macrocycle, is poorly soluble in anhydrous
alcohols and acetone. Methylated CDs from DS≈ 8 are also
soluble in halogenated organic solvents, which can be uti-
lized in their purification processes.
3.2. CD Derivatives Are Soluble in Organic Solvents Only
The number of organic solvent-soluble CD derivatives
reported in skin applications has been restricted for a
long time to the heptakis(2,6-di-O-ethylated) (DIETB) (62-
64) and the peracetylated (65) βCDs (PerAcCDs) only. The
syntheses of these CDs are summarized in Figures 2A and
3. These CDs are insoluble in water, and the hydrophilic
profile of the naked CDs is reversed: the cavity is more hy-
drophilic than the substituted hydroxyl rims. The relative
higher hydrophilicity of the cavity allows the controlled
release of hydrophilic drugs, although it is also true that
their penetration through the skin is very limited (14, 62-
65). These CDs are appropriate for topical applications,
which are mainly targeted by the cosmetic and skin care
formulations.
Dried PerAcCDs are soluble in water-free alcohols, ace-
tone, halogenated solvents, and even in toluene. Since Per-
AcCDs are capable of forming a complex with water, this
complex formation significantly reduces their alcohol sol-
ubilities and accelerates the formation of the toluene com-
plex (37). The toluene complexation is depending on the
residual water content, which allows for the effective re-
moval of the synthesis impurities. The preparation of DI-
ETB requires more sophisticated reaction conditions and
complicated work-up processes, using different organic
solvents than the PerAcCDs. The preparation is similar to
the methylated version, as seen in Figure 2A. The highly
hydrophobic DIETB makes its purification difficult, which
causes limited application potential. Since the crude prod-
uct is soluble in hexanes, the heptakis version slowly pre-
cipitates, leaving the residual reagent, solvents, and the
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majority of the randomly substituted versions dissolved.
Although this results in a higher heptakis content as com-
pared to DIMEB, further purification is more difficult and
increases its production costs.
3.3. Insoluble CD Derivatives
The insoluble CD polymers (CDPIS) have a 3D network
of CDs linked by the spacer and are practically insoluble
in all solvents. The insoluble nature of these CD deriva-
tives also restricts their non-destructive analytical studies,
which turns their structural characterization to a compli-
cated task. Although the synthesis of CDPIS uses the same
linker as the soluble ones, the number of linkers, their spa-
tial arrangement, and the surface components are even
more difficult to determine. The synthetic methods are
practically identical with the soluble versions shown in
Figure 2B, only the CD/crosslinker molar ratio is different.
The production of well-defined structures with uniform
particles is usually very complicated, though this complex-
ity is rather technical than chemical. Surfactants, such as
alkanols (e.g., n-butanol) and/or mineral oils are applied
to control the particle sizes of the product in the polymer-
ization reaction, resulting in nice, uniform beads, like the
ion-exchanger resins, as in Figure 4A (53, 66-68). Although
these beads have excellent adsorption properties, they are
physically quite vulnerable. Intensive physical destruction
of the beads occurs upon dehydration, caused by either sol-
vents or moderately high temperature. The preparation
method of the insoluble bead polymer is not obvious, and
the hard reproducibility of the synthesis results in difficult
accessibility from commercial sources. Although the bead
polymer is useful in various preparations, its usability in
skin formulations is limited.
The powder form of CDPIS is more suitable for various
skin formulations. Under the conventional reaction con-
ditions, the powder is complicated to prepare. Recently,
a solvent-free, green chemical method (69) has been pub-
lished for the production of standardized CDPIS powder,
which is likely to provide greater potential for CDPIS in ex-
tracorporeal preparations. The powdered form is prepared
more effectively with a reduced CD/reagent ratio, relative
to the bead polymer. Although CDPIS powder has a slightly
lower complexing ability than the pearls, due to its ad-
vantageous physicochemical properties, it can range from
medical applications to skin care and cosmetics by the ad-
vantage of controlled weighing and uniformity. Small par-
ticles (Figure 4B) are also suitable for the controlled release
of drugs. Particles have almost zero zeta-potential in water
that can be finely tuned with electrolytes to reach favorable
association properties of the powder.
Insoluble ester-type nanosponge, citric acid linked
βCDs, has also been reported (70). Although the solid
nanosponge chemical stability is better than the soluble
ones, the hydrolyzable chemical bond restricts a wider uti-
lization. The characterization of insoluble nanosponges is
even less sophisticated than the soluble versions.
4. Conclusions
The poor transdermal absorption of CDs makes them a
promising drug ingredient in skin preparations. Over the
past nearly 50 years, the number of CD derivatives in der-
mal compositions has remained essentially unchanged.
This is somehow understandable by the small number of
pharmaceutically acceptable CDs, although a larger num-
ber of newly targeted CD derivatives could have been ex-
pected due to the milder toxicological requirements. Many
CDs are widely used in everyday products, and their prolif-
eration in skin products will also be evident soon. The reso-
lution of the difficult, sometimes problematic, laboratory-
level synthetic reproducibility and full characterization of
CDPIS could be a big step in dermal utilizations, but this
requires further intensive research.
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